Reading ALNY? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ALNY free→Reading ALNY? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ALNY free→QuarterlyIQ Insights · ALNY
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers. Effective as of June 1, 2026, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from ten to eleven and elected Benjamin F. Cravatt, Ph.D. to fill the newly created vacancy. Dr. Cravatt…
shall be deemed to be furnished, and not filed: 99.1 Press Release dated April 30, 2026 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 30, 2026 ALNYLAM PHARMACEUTICALS, INC. By: /s/ Jeffrey V. Poulton Jeffrey V. Poulton Executive Vice President, Chief Fin…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective March 2, 2026 (the “Grant Date”), the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) granted, following the recommendation of the People, Culture and Compensation Committee (the “Committee”), a special equity award (the “Special Award”) under the Company’s Second Amended and Restated 2018 St…
shall be deemed to be furnished, and not filed: 99.1 Press Release dated February 12, 2026 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 12, 2026 ALNYLAM PHARMACEUTICALS, INC. By: /s/ Jeffrey V. Poulton Jeffrey V. Poulton Executive Vice President, Chi…
Results of Operations and Financial Condition. On January 11, 2026, Alnylam Pharmaceuticals, Inc. (the “Company”) announced its new five-year strategy, “ Alnylam 2030, ” as well as its preliminary fourth quarter and full year 2025 global net product revenues of approximately $995 million and $2,987 million, respectively, for AMVUTTRA® (vutrisiran), ONPATTRO® (patisiran), GIVLAARI® (givosiran) and OXLUMO® (lumasiran), and provided the Company’s 2026 product and pipeline goals. The Company also…
Other Events. On December 10, 2025, Alnylam Pharmaceuticals, Inc. (the “Company”) entered into separate, privately negotiated repurchase agreements with certain holders of its 1.00% convertible senior notes due 2027 (the “Notes”) to repurchase for cash (the “Repurchases”) approximately $34.4 million aggregate principal amount of the Notes for a total repurchase cost (including accrued and unpaid interest) of approximately $51.9 million. The final aggregate cash repurchase price is subject to…
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers On December 2, 2025, Michael W. Bonney and Carolyn Bertozzi, Ph.D. provided notice of each of their resignations from the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), effective on the same date. Neither Mr. Bonney’s nor Dr. Bertozzi’s respective resignation was caused by any disagreement with the Company on…
shall be deemed to be furnished, and not filed: 99.1 Press Release dated October 30, 2025 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 30, 2025 ALNYLAM PHARMACEUTICALS, INC. By: /s/ Jeffrey V. Poulton Jeffrey V. Poulton Executive Vice President, Chief…
Entry into a Material Definitive Agreement. On September 30, 2025 (the “Closing Date”), Alnylam Pharmaceuticals, Inc. (the “Company”) entered into a Credit Agreement (the “Credit Agreement”) among the lenders party thereto, Bank of America, N.A., as Administrative Agent, and the other parties named therein. The Credit Agreement provides for a $500.0 million revolving line of credit (the “Revolving Credit Facility”), including a $150.0 million letter of credit sublimit. The Credit Agreement pr…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained in
Entry Into or Amendment of a Material Definitive Agreement. Indenture and Notes On September 12, 2025, Alnylam Pharmaceuticals, Inc. (the “Company”) completed its previously announced offering of $575.0 million in aggregate principal amount of 0.00% Convertible Senior Notes due 2028 (the “Initial Notes”). On September 10, 2025, the initial purchasers in such offering exercised their option to purchase an additional $86.25 million in aggregate principal amount of the Company’s 0.00% Convertibl…
Unregistered Sales of Equity Securities. The information set forth under
Creation of a Direct Financial Obligation or an Off-Balance Sheet Arrangement. The information set forth under
Other Events. Concurrently with the pricing of the Notes, the Company entered into privately negotiated transactions (the “note repurchase transactions”) with certain holders of the Company’s 1.00% convertible senior notes due 2027 (the “existing notes”) to repurchase for cash approximately $637.8 million aggregate principal amount of the existing notes for a total repurchase cost (including accrued and unpaid interest) of approximately $1,105.8 million. The terms of each note repurchase tran…
Other Events. On September 8, 2025, Alnylam Pharmaceuticals, Inc. (the “Company”) issued a press release relating to the commencement of its proposed offering of convertible senior notes due 2028 to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Convertible Note Offering”). On September 9, 2025, the Company issued a press release relating to the pricing of the Convertible Note Offering. Copies of the pr…
shall be deemed to be furnished, and not filed: 99.1 Press Release dated July 31 , 2025 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 31, 2025 ALNYLAM PHARMACEUTICALS, INC. By: /s/ Jeffrey V. Poulton Jeffrey V. Poulton Executive Vice President, Chief Fina…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 12, 2025, the People, Culture and Compensation Committee (the “Committee”) of the Board of Directors of Alnylam Pharmaceuticals, Inc. (the “Company”) approved certain compensatory arrangements in connection with the combination of the Company’s Research and Early Development function and its Development function into a single organization (…
shall be deemed to be furnished, and not filed: 99.1 Press Release dated May 1, 2025 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 1, 2025 ALNYLAM PHARMACEUTICALS, INC. By: /s/ Jeffrey V. Poulton Jeffrey V. Poulton Executive Vice President, Chief Financial…
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers On March 3, 2025, Phillip A. Sharp, Ph.D. informed the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”) of his retirement from the Board, effective as of May 8, 2025. Dr. Sharp’s retirement was not caused by any disagreement with the Company on any matter relating to the Company’s operations, policies or practice…
shall be deemed to be furnished, and not filed: 99.1 Press Release dated February 13, 2025 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 13, 2025 ALNYLAM PHARMACEUTICALS, INC. By: /s/ Jeffrey V. Poulton Jeffrey V. Poulton Executive Vice President, Chi…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.